SciNeuro Pharma inks license deal with GSK

02-06-2022Comments (0)Print

23-06-2022

03-07-2021

29-06-2021

15-04-2021

26-06-2020

04-11-2019

05-06-2023

10-02-2022

24-01-2022

02-02-2021

China-based CNS drug developer SciNeuro Pharmaceuticals yesterday announced the execution of an exclusive, worldwide license and option agreement with UK pharma major GlaxoSmithKline (LSE: GSK).

The agreement focuses on inhibitors of Lp-PLA2, an enzyme that has been implicated in the pathogenesis of neurodegenerative diseases. Clinical findings suggest that inhibition of Lp-PLA2 activity may improve cognitive function in subjects with Alzheimer's disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

• All the news that moves the needle in pharma and biotech.• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. • Receive The Pharma Letter daily news bulletin, free forever.

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.• Daily roundup of key events in pharma and biotech.• Monthly in-depth briefings on Boardroom appointments and M&A news.• Choose from a cost-effective annual package or a flexible monthly subscription.

Asia PacificBiotechnologyChinaCNS DiseasesDealsFocus OnGSKLicensingNeurologicalResearchSciNeuro PharmaceuticalsUK

News